New Two-Drug combo enters human testing for obesity and diabetes
NCT ID NCT06924320
Summary
This early-stage study is testing the safety and how the body processes a new two-drug combination (MET233 and MET097) for weight management. It will enroll 132 adults with obesity or who are overweight, including some with type 2 diabetes. The main goal is to see if the treatment is safe and well-tolerated, while also checking for early signs of weight loss.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY AND OBESITY-RELATED MEDICAL CONDITIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site MET233/097 24-101-001
RECRUITINGCypress, California, 90630, United States
Conditions
Explore the condition pages connected to this study.